MX2019010999A - Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas. - Google Patents

Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas.

Info

Publication number
MX2019010999A
MX2019010999A MX2019010999A MX2019010999A MX2019010999A MX 2019010999 A MX2019010999 A MX 2019010999A MX 2019010999 A MX2019010999 A MX 2019010999A MX 2019010999 A MX2019010999 A MX 2019010999A MX 2019010999 A MX2019010999 A MX 2019010999A
Authority
MX
Mexico
Prior art keywords
formulations
making
methods
binding proteins
antibodies
Prior art date
Application number
MX2019010999A
Other languages
English (en)
Spanish (es)
Inventor
R Foss Willard
Ping DAI Xiao-
Banks Douglas
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63678296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2019010999A publication Critical patent/MX2019010999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2019010999A 2017-03-29 2018-03-28 Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas. MX2019010999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478524P 2017-03-29 2017-03-29
PCT/US2018/024787 WO2018183459A1 (en) 2017-03-29 2018-03-28 Formulations comprising pd-1 binding proteins and methods of making thereof

Publications (1)

Publication Number Publication Date
MX2019010999A true MX2019010999A (es) 2020-02-05

Family

ID=63678296

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010999A MX2019010999A (es) 2017-03-29 2018-03-28 Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas.

Country Status (16)

Country Link
US (1) US20180289802A1 (enExample)
EP (1) EP3601338A4 (enExample)
JP (1) JP2020512359A (enExample)
KR (1) KR20190141658A (enExample)
CN (1) CN110678482A (enExample)
AU (1) AU2018246252A1 (enExample)
BR (1) BR112019018996A2 (enExample)
CA (1) CA3055984A1 (enExample)
CL (1) CL2019002605A1 (enExample)
CO (1) CO2019010230A2 (enExample)
EA (1) EA201991912A1 (enExample)
EC (1) ECSP19076344A (enExample)
IL (1) IL268884A (enExample)
MX (1) MX2019010999A (enExample)
SG (1) SG11201907948TA (enExample)
WO (1) WO2018183459A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
AU2016332725A1 (en) 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
US20230143066A1 (en) * 2020-04-17 2023-05-11 Ono Pharmaceutical Co., Ltd. Method for removing color from drug substance of protein preparation
LT4157876T (lt) 2020-05-26 2024-10-25 Boehringer Ingelheim International Gmbh Anti-pd-1 antikūnai
MX2023001160A (es) * 2020-07-31 2023-02-22 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
EP4008345A1 (en) * 2020-12-03 2022-06-08 Hexal AG Novel formulations for antibodies
CN116019907A (zh) * 2021-07-29 2023-04-28 上海君实生物医药科技股份有限公司 抗pd-1抗体药物组合物及其用途
CN117088981B (zh) * 2023-08-15 2024-09-10 福建医科大学附属协和医院 抗b7-h3的单链抗体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241745A1 (en) * 2001-07-31 2004-12-02 Tasuku Honjo Substance specific to pd-1
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2008047914A1 (fr) * 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
NZ600758A (en) * 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2604280A3 (en) * 2008-03-27 2013-10-16 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
HRP20180045T1 (hr) * 2008-10-02 2018-03-23 Aptevo Research And Development Llc Proteini antagonisti cd86 koji se vežu na više meta
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
RS59880B1 (sr) * 2013-09-27 2020-03-31 Hoffmann La Roche Formulacije za anti-pdl1 antitelo
CA2932515C (en) * 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
NZ735820A (en) * 2015-04-17 2025-02-28 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
AU2016332725A1 (en) * 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
US10751414B2 (en) * 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
JP2019534859A (ja) * 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法

Also Published As

Publication number Publication date
IL268884A (en) 2019-10-31
ECSP19076344A (es) 2019-10-31
WO2018183459A1 (en) 2018-10-04
CL2019002605A1 (es) 2020-05-29
CA3055984A1 (en) 2018-10-04
US20180289802A1 (en) 2018-10-11
CO2019010230A2 (es) 2020-01-17
EP3601338A4 (en) 2020-12-16
EP3601338A1 (en) 2020-02-05
JP2020512359A (ja) 2020-04-23
AU2018246252A1 (en) 2019-09-19
CN110678482A (zh) 2020-01-10
KR20190141658A (ko) 2019-12-24
SG11201907948TA (en) 2019-09-27
BR112019018996A2 (pt) 2020-04-14
EA201991912A1 (ru) 2020-03-10

Similar Documents

Publication Publication Date Title
MX2019010999A (es) Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas.
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
CA2971734C (en) Anti-pd-1 antibodies
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12018501882A1 (en) Binding proteins and methods of use thereof
SA522431756B1 (ar) Tigit أجسام مضادة لـ
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
CA2914087C (en) Anti-PD-1 antibodies and their methods of use
PH12017502180A1 (en) Tau-binding antibodies
MX372817B (es) Anticuerpos dirigidos contra la proteína muerte programada-1 (pd-1).
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
PH12017502207B1 (en) Tau-binding antibodies
IL272103A (en) Antigen-binding proteins binding to 5T4 and 4-1BB, compositions and methods
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
PH12017502277A1 (en) Multi-specific binding proteins
AU2017234528A8 (en) Neutralizing monoclonal antibodies to IL-25 and uses thereof
MA40526A (fr) Protéines de fixation antigénique fixant le cxcr3
EA201891989A1 (ru) Антитела к tigit
HK40027265A (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods